We divide this work into four main sections: we first discuss the existing preclinical and clinical landscape of CARs targeting conventional antigens in GBM, such as the interleukin-13 receptor α2(IL13Rα2) and the epidermal growth factor receptor (EGFR). This evidence concerns the gene EGFR and glioblastoma.